[go: up one dir, main page]

AR058532A1 - Tratamientos de trastornos neurodegenerativos - Google Patents

Tratamientos de trastornos neurodegenerativos

Info

Publication number
AR058532A1
AR058532A1 ARP060105199A ARP060105199A AR058532A1 AR 058532 A1 AR058532 A1 AR 058532A1 AR P060105199 A ARP060105199 A AR P060105199A AR P060105199 A ARP060105199 A AR P060105199A AR 058532 A1 AR058532 A1 AR 058532A1
Authority
AR
Argentina
Prior art keywords
neurodegenerative disorders
treatments
arg
peptides
glu
Prior art date
Application number
ARP060105199A
Other languages
English (en)
Inventor
Rose Steven P Russell
Radmila Mileusnic
Original Assignee
Univ Open
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Open filed Critical Univ Open
Publication of AR058532A1 publication Critical patent/AR058532A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos que tienen la secuencia D-Arg-L-Glu-L-Arg. O la secuencia L-Arg-F-Glu-L-Arg y derivados de dichos péptidos. Dichos péptidos son utiles en el tratamiento de trastornos neurodegenerativos y como mejoradores de la cognicion. Se prefieren los péptidos que incluyen un grupo protector.
ARP060105199A 2005-11-25 2006-11-24 Tratamientos de trastornos neurodegenerativos AR058532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0524023A GB2432586B (en) 2005-11-25 2005-11-25 Treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AR058532A1 true AR058532A1 (es) 2008-02-06

Family

ID=35601208

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105199A AR058532A1 (es) 2005-11-25 2006-11-24 Tratamientos de trastornos neurodegenerativos

Country Status (13)

Country Link
US (1) US20090221513A1 (es)
EP (1) EP1959980A2 (es)
JP (1) JP2009517376A (es)
CN (1) CN101351214A (es)
AR (1) AR058532A1 (es)
AU (1) AU2006318834A1 (es)
BR (1) BRPI0618994A2 (es)
CA (1) CA2630922A1 (es)
GB (1) GB2432586B (es)
IL (1) IL191681A0 (es)
MX (1) MX2008006773A (es)
WO (1) WO2007060486A2 (es)
ZA (1) ZA200805108B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5634062B2 (ja) * 2009-12-28 2014-12-03 カルピス株式会社 脳機能改善用組成物および脳機能を改善する方法
JP5755436B2 (ja) * 2010-12-03 2015-07-29 日本サプリメント株式会社 記憶増強剤および記憶力を増強する方法
JP5643624B2 (ja) * 2010-12-03 2014-12-17 日本サプリメント株式会社 記憶増強剤および記憶力を増強する方法
EP2919760A4 (en) * 2012-11-19 2016-08-03 Technion Res & Dev Foundation LIPOSOMES FOR IN VIVO RELEASE
GB201613999D0 (en) * 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
GB9917725D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
EP2228388A1 (en) * 2001-04-18 2010-09-15 The Open University Protected Arg-Glu-Arg polypeptides and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
WO2004028548A2 (en) * 2002-09-26 2004-04-08 Carbomer, Inc. Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents

Also Published As

Publication number Publication date
GB2432586B (en) 2010-01-13
JP2009517376A (ja) 2009-04-30
CA2630922A1 (en) 2007-05-31
MX2008006773A (es) 2009-01-21
GB2432586A (en) 2007-05-30
GB0524023D0 (en) 2006-01-04
IL191681A0 (en) 2009-02-11
ZA200805108B (en) 2009-03-25
WO2007060486A2 (en) 2007-05-31
AU2006318834A1 (en) 2007-05-31
BRPI0618994A2 (pt) 2011-09-20
CN101351214A (zh) 2009-01-21
WO2007060486A3 (en) 2007-09-07
US20090221513A1 (en) 2009-09-03
EP1959980A2 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1121136T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2014002518A1 (es) Compuestos derivados heterociclicos nitrogenados, inhibidores de la bace-1 o de la bace-2; composicion farmaceutica que los comprende; combinacion farmaceutica; su uso en el tratamiento o prevencion de la enfermedad de alzheimer o un deterioro cognitivo leve.
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CR10433A (es) Compuestos organicos y sus usos
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
PT2322546E (pt) Compostos glp-1 acilados
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
CR10336A (es) Compuestos organicos y sus usos
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
DK2190473T3 (da) Peptid med reduceret dimerdannelse
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales

Legal Events

Date Code Title Description
FB Suspension of granting procedure